Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility TEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) —